Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Tom Button"'
Autor:
Stephen Lee, Tom Button
Publikováno v:
MSOR Connections. 18:33-35
The Further Pure with Technology unit has been updated and is still available as an optional component for Further Mathematics students and in this short update we will address its role and how it can support pre-university students in developing the
Autor:
Joanne L. Jones, Declan T. Chard, Arman Eshaghi, Alasdair Coles, M Pardini, Claudia Am Gandini Wheeler-Kingshott, J William L Brown, Ferran Prados Carrasco, Rebecca S. Samson, Tom Button, Sebastien Ourselin, Carole H. Sudre
Background: In multiple sclerosis (MS), disease effects on magnetisation transfer ratio (MTR) increase towards the ventricles. This periventricular gradient is evident shortly after first symptoms and is independent of white matter lesions. Objective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e93ed7799bd3b31476ccf70e3a27276c
http://hdl.handle.net/11567/962589
http://hdl.handle.net/11567/962589
Autor:
Tom Button
Develop a deeper understanding of mathematical concepts and their applications with new and updated editions from our bestselling series.- Build connections between topics using real-world contexts that develop mathematical modelling skills, thus pro
Autor:
Alasdair Coles, I. Bjornson, L. Costelloe, Michael T. Fahey, Onajite Kousin-Ezewu, Laura Azzopardi, Orla Tuohy, Neil Robertson, Katharine Harding, Grant A. Hill-Cawthorne, K. May, D. A. S. Compston, Tom Button, Joanne L. Jones
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 86:208-215
OBJECTIVES: Alemtuzumab is a newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe, which in phase II and III studies demonstrated superior efficacy over β-interferon in reducing disability progression over 2-3 y
Autor:
Tom Button, K Hunter, Daniel J. Tozer, Catherine M. Dalton, Alasdair Coles, David Miller, Alastair Compston, Daniel R. Altmann
Publikováno v:
Multiple Sclerosis Journal. 19:241-244
The magnetization transfer ratio reflects the integrity of tissue structure, including myelination and axonal density. Mean magnetization transfer ratio fell in 18 untreated patients with multiple sclerosis both in normal appearing grey (-0.25 pu/yea
Autor:
Joanne L. Jones, Orla Tuohy, Grant A. Hill-Cawthorne, Tom Button, Alasdair Coles, Karen May, D Alastair S Compston, Gavin Giovannoni, Michael T. Fahey, Jennifer Somerfield, Alison Green
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 83:298-304
Background Alemtuzumab is a lymphocyte depleting monoclonal antibody that has demonstrated superior efficacy over interferon β-1a for relapsing–remitting multiple sclerosis (MS), and is currently under investigation in phase 3 trials. One unresolv
Autor:
Tom Button, Alasdair Coles
Publikováno v:
Future Neurology. 5:177-188
Alemtuzumab is a humanized monoclonal antibody against CD52, an antigen found on lymphocytes and monocytes. Pulsed administration causes prolonged T-cell depletion and has been shown to be effective in early relapsing–remitting multiple sclerosis,
Autor:
Tom Button, Stephen Lee
Publikováno v:
MSOR Connections. 13:3-5
Mathematics in Education and Industry (MEI) celebrate 50 years of existence in 2013. Over that time much has changed in the world of education, but MEI continue to play its part in being innovative in developing support for the teaching and learning
Autor:
Tom Button
Publikováno v:
Neuromuscular Disorders. 27:200
Autor:
Klaus Schmierer, Alasdair Coles, Daniel J. Tozer, Tom Button, David Miller, Daniel R. Altmann, Claudia A. M. Wheeler-Kingshott, K Hunter
Publikováno v:
Multiple sclerosis and related disorders. 3(2)
Background Enhancing remyelination in MS might improve function and protect axons from future damage. Lesion magnetisation transfer ratio (MTR) is sensitive to myelin content, and may be a useful measure for trials evaluating potential remyelinating